The use of multiple cost-effectiveness thresholds in pharmacoeconomic evaluation is a hotly debated topic in the international academic community. This study analyzed and discussed thresholds in the context of pharmacoeconomic evaluation and reimbursement decision-making. We suggest that the thresholds inferred from reimbursement decisions should be distinguished from cost-effectiveness threshold in pharmacoeconomic evaluation. Pharmacoeconomic evaluations should adopt a fixed threshold, which should not vary with the subjects evaluated. This would help avoid the invitation of numerous cost-effectiveness thresholds for a specific drug, an exceptional disease, a type of innovation, or a certain level of malignancy, which misleads economic evaluation adopting restless changing standards and making pharmacoeconomic evaluation and decision-making more complex and contradictory.
CITATION STYLE
Sun, L., Peng, X., Li, S., & Huang, Z. (2023, December 1). Cost-effectiveness thresholds or decision-making threshold: a novel perspective. Cost Effectiveness and Resource Allocation. BioMed Central Ltd. https://doi.org/10.1186/s12962-023-00472-6
Mendeley helps you to discover research relevant for your work.